Belgium's Ablynx, which is developing a pipeline of Nanobody-based therapeutics, is planning to go public. There's no word on how big the offering is intended to be, but the biotech has raised close to $100 million in venture funds to develop tiny antibody-based therapies. Nanobodies, explains Ablynx, are a class of therapeutic proteins based on single-domain antibody fragments which have been generated against more than 100 different disease targets.
- check out the release [1] on the IPO plans
Related Articles:
Boehringer, Ablynx team up on nanobodies. Report [2]
Ablynx inks $265M 'nanobody' development deal. Report [3]
Ablynx inks licensing deal for nanobodies. Report [4]
Ablynx pockets $50M in third round. Report [5]
Read more on: Ablynx [6] | Nanotechnology [7]
Links:
[1] http://media.huginonline.com/plsql/try/pr_online.pressrelease?p_message_id=1159021
[2] http://www.fiercebiotech.com/story/boehringer-ablynx-team-up-on-nanobodies/2007-09-07?utm_medium=nl&utm_source=link
[3] http://www.fiercebiotech.com/story/ablynx-inks-265m-nanobody-development-deal/2007-01-08?utm_source=related&utm_medium=internal
[4] http://www.fiercebiotech.com/story/ablynx-inks-licensing-deal-for-nanobodies/2006-11-06
[5] http://www.fiercebiotech.com/story/ablynx-pockets-50m-in-third-round/2006-08-23
[6] http://www.fiercebiotech.com/tags/ablynx
[7] http://www.fiercebiotech.com/tags/nanotechnology